- Toll Free: +1-800-792-5285
- (UK): +44-845-528-1300
- Int'l: +1-503-894-6022
- Help@alliedmarketresearch.com
Cart
|
LI_183721
|
Pages: NA
|
Dec 2018 | 729 Views
|
|
|
|
Author's :
NA
|
Tables: NA
|
Charts: NA
|
Formats*: |
|
Acute myeloid leukemia (AML), is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also start in other types of blood-forming cells. In AML, there is a fast production of the abnormal WBCs that get accumulated in the bone marrow, and affect the production of normal blood cells.
The major factors that drive the market growth include advantages of biopharmaceuticals over conventional medicines, rise in geriatric population, unhealthy lifestyle, strong biopharmaceutical pipeline, and development of combination therapies that can treat diseases that were previously untreated. However, high cost of the therapeutic process, and its safety concerns, is expected to hinder the growth of the market. Moreover, ongoing researches have led to discovery of more efficient therapies for cancer treatment, which pose attractive opportunities for the key market players.
The global acute myeloid leukemia therapeutics market is segmented on the basis of treatment type and geography. According to treatment type, the market is divided into cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, hormonal therapy, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key players profiled in the report include Eli Lilly and Company, Genzyme Corporation, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Celegene Corporation, Cephalon, Inc., and Eisai Inc.
Key Benefits
Chapter 1 INTRODUCTION
1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
Chapter 2 EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
Chapter 3 MARKET OVERVIEW
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top Player Positioning/ Market Share Analysis, 2017
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Drug Pipeline Analysis
Chapter 4 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy Drugs
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Cytarabine
4.2.2.1.1. Market size and forecast
4.2.2.2. Gleevac
4.2.2.2.1. Market size and forecast
4.2.2.3. Sprycel
4.2.2.3.1. Market size and forecast
4.2.2.4. Fludara
4.2.2.4.1. Market size and forecast
4.2.2.5. Others
4.2.2.5.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.3. Anthracycline Drugs
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Daunomycin
4.3.2.1.1. Market size and forecast
4.3.2.2. Idarubicin
4.3.2.2.1. Market size and forecast
4.3.2.3. Mitoxantrone
4.3.2.3.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.4. Hormonal Therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
Chapter 5 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral Drugs
5.2.1. Market size and forecast
5.3. Intravenous Drugs
5.3.1. Market size and forecast
5.4. Others
5.4.1. Market size and forecast
Chapter 6 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY GEOGRAPHY
6.1. Overview
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America acute myeloid leukemia therapeutics market, by country
6.2.2.1. U.S. acute myeloid leukemia therapeutics market
6.2.2.2. Canada acute myeloid leukemia therapeutics market
6.2.2.3. Mexico acute myeloid leukemia therapeutics market
6.2.3. North America acute myeloid leukemia therapeutics market, by type
6.2.4. North America acute myeloid leukemia therapeutics market, by route of administration
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe acute myeloid leukemia therapeutics market, by country
6.3.2.1. Germany acute myeloid leukemia therapeutics market
6.3.2.2. France acute myeloid leukemia therapeutics market
6.3.2.3. UK acute myeloid leukemia therapeutics market
6.3.2.4. Italy acute myeloid leukemia therapeutics market
6.3.2.5. Spain acute myeloid leukemia therapeutics market
6.3.2.6. Rest of Europe acute myeloid leukemia therapeutics market
6.3.3. Europe acute myeloid leukemia therapeutics market, by type
6.3.4. Europe acute myeloid leukemia therapeutics market, by route of administration
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific acute myeloid leukemia therapeutics market, by country
6.4.2.1. Japan acute myeloid leukemia therapeutics market
6.4.2.2. China acute myeloid leukemia therapeutics market
6.4.2.3. India acute myeloid leukemia therapeutics market
6.4.2.4. Australia acute myeloid leukemia therapeutics market
6.4.2.5. South Korea acute myeloid leukemia therapeutics market
6.4.2.6. Rest of Asia-Pacific acute myeloid leukemia therapeutics market
6.4.3. Asia-Pacific acute myeloid leukemia therapeutics market, by type
6.4.4. Asia-Pacific acute myeloid leukemia therapeutics market, by route of administration
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA acute myeloid leukemia therapeutics market, by country
6.5.2.1. Brazil acute myeloid leukemia therapeutics market
6.5.2.2. Saudi Arabia acute myeloid leukemia therapeutics market
6.5.2.3. South Africa acute myeloid leukemia therapeutics market
6.5.2.4. Rest of LAMEA acute myeloid leukemia therapeutics market
6.5.3. LAMEA acute myeloid leukemia therapeutics market, by type
6.5.4. LAMEA acute myeloid leukemia therapeutics market, by route of administration
Chapter 7 COMPANY PROFILES
7.1. Ambit Biosciences Corporation
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. Celgene Corporation
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. Teva Pharmaceutical Industries Ltd.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. Clavis Pharma ASA
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. Eisai Co., Ltd.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. Sanofi
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. Sunesis Pharmaceuticals, Inc.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. Novartis AG
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. Bristol-Myers Squibb
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. F. Hoffmann-La Roche AG
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Enterprise
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high level data integrity, accurate analysis and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
